NCT07160491 Early Thrombolysis Guided by AI-Assisted App in Patients With STEMI
| NCT ID | NCT07160491 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shenyang Northern Hospital |
| Condition | STEMI - ST Elevation Myocardial Infarction |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,356 participants |
| Start Date | 2025-09-08 |
| Primary Completion | 2029-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,356 participants in total. It began in 2025-09-08 with a primary completion date of 2029-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to elucidate whether guiding by a novel artificial intelligence assisted mobile application can improve the clinical outcomes of patients in whom "guide wire passing through the lesion" could not be achieved within 120 min after diagnosis of STEMI, compared to conventional treatment strategies. With concerns of the inadequate use of thrombolysis in patients with STEMI in China, this study applies a new artificial intelligence assisted mobile application to guide the process of thrombolysis combined with PCI treatment, in order to accomplish the rapid coordination and cooperation of the whole medical network during re-perfusion treatment in different regions and different medical institutions in China, increases the proportion of early thrombolysis in pre-hospital setting, shortens the time from STEMI onset to reperfusion, and provides a reliable, effective and replicable new strategy for promoting and optimizing early reperfusion.
Eligibility Criteria
Inclusion Criteria: * (the following inclusion conditions shall be met at the same time): 1. age: ≥ 18 years and ≤ 80 years; 2. Chest pain lasted for more than 30 min, and the onset time of chest pain was ≤ 12 hours; 3. ECG: ST segment elevation after J-point in 2 or more adjacent leads: limb leads ≥ 0.1 mv or chest leads ≥ 0.2 mv; 4. it is expected that "guide wire passing through the lesion" could not be achieved within 120 min after the diagnosis of STEMI; 5. Signed informed consent . Exclusion Criteria: * (1) Cardiac rupture; (2) Complete left bundle branch block (LBBB) or ventricular pacing; (3) There are contraindications to thrombolysis; (4) Have serious comorbidities; (5) Have complex heart disease; (6) There are situations that are not suitable for clinical trials.
Contact & Investigator
Yaling Han, MD,PhD
STUDY CHAIR
Northern Theater Command General Hospital of the People's Liberation Army
Frequently Asked Questions
Who can join the NCT07160491 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying STEMI - ST Elevation Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07160491 currently recruiting?
Yes, NCT07160491 is actively recruiting participants. Contact the research team at xukai2001@sina.com for enrollment information.
Where is the NCT07160491 trial being conducted?
This trial is being conducted at Shenyang, China.
Who is sponsoring the NCT07160491 clinical trial?
NCT07160491 is sponsored by Shenyang Northern Hospital. The principal investigator is Yaling Han, MD,PhD at Northern Theater Command General Hospital of the People's Liberation Army. The trial plans to enroll 3,356 participants.